DERMATA THERAPEUTICS INC (DRMA) Stock Price, Quote, News and Overview
NASDAQ:DRMA - Nasdaq - US2498454055 - Common Stock - Currency: USD
DRMA Quote, Performance and Key Statistics
0.75
+0.01 (+0.81%)
The current stock price of DRMA is 0.75 USD. In the past month the price decreased by -0.27%. In the past year, price decreased by -80.44%.
DRMA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.08 | 328.06B | ||
| AMGN | AMGEN INC | 13.46 | 150.26B | ||
| GILD | GILEAD SCIENCES INC | 14.09 | 135.70B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.53B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.61 | 65.13B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.83B | ||
| ARGX | ARGENX SE - ADR | 98.77 | 35.40B | ||
| ONC | BEIGENE LTD-ADR | 6.1 | 25.76B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.69B | ||
| NTRA | NATERA INC | N/A | 21.46B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.04B | ||
| BIIB | BIOGEN INC | 8.12 | 18.81B |
Related stock screener links
About DRMA
Company Profile
Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. The company is headquartered in San Diego, California and currently employs 8 full-time employees. The company went IPO on 2021-08-13. The firm is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.
Company Info
DERMATA THERAPEUTICS INC
3525 Del Mar Heights Rd., #322
San Diego CALIFORNIA US
CEO: Gerald T. Proehl
Employees: 8
Phone: 18582230882
DERMATA THERAPEUTICS INC / DRMA FAQ
What is the stock price of DERMATA THERAPEUTICS INC today?
The current stock price of DRMA is 0.75 USD. The price increased by 0.81% in the last trading session.
What is the ticker symbol for DERMATA THERAPEUTICS INC stock?
The exchange symbol of DERMATA THERAPEUTICS INC is DRMA and it is listed on the Nasdaq exchange.
On which exchange is DRMA stock listed?
DRMA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for DERMATA THERAPEUTICS INC stock?
7 analysts have analysed DRMA and the average price target is 6.12 USD. This implies a price increase of 716% is expected in the next year compared to the current price of 0.75. Check the DERMATA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is DERMATA THERAPEUTICS INC worth?
DERMATA THERAPEUTICS INC (DRMA) has a market capitalization of 4.79M USD. This makes DRMA a Nano Cap stock.
How many employees does DERMATA THERAPEUTICS INC have?
DERMATA THERAPEUTICS INC (DRMA) currently has 8 employees.
What are the support and resistance levels for DERMATA THERAPEUTICS INC (DRMA) stock?
DERMATA THERAPEUTICS INC (DRMA) has a support level at 0.75 and a resistance level at 0.78. Check the full technical report for a detailed analysis of DRMA support and resistance levels.
Should I buy DERMATA THERAPEUTICS INC (DRMA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of DRMA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of DRMA, evaluating the profitability, health, valuation and growth aspects
- DERMATA THERAPEUTICS INC (DRMA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- DERMATA THERAPEUTICS INC (DRMA) Sales and EPS estimates to see what analysts future expectations are.
- DERMATA THERAPEUTICS INC (DRMA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- DERMATA THERAPEUTICS INC (DRMA) Insider and Institutional Ownership to learn about the owners and their transactions.
- DERMATA THERAPEUTICS INC (DRMA) Stock Chart to make your own analysis
- DERMATA THERAPEUTICS INC (DRMA) Latest news and press-releases to stay up to date.
Does DERMATA THERAPEUTICS INC (DRMA) stock pay dividends?
DRMA does not pay a dividend.
What is the Price/Earnings (PE) ratio of DERMATA THERAPEUTICS INC (DRMA)?
DERMATA THERAPEUTICS INC (DRMA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-8.73).
What is the Short Interest ratio of DERMATA THERAPEUTICS INC (DRMA) stock?
The outstanding short interest for DERMATA THERAPEUTICS INC (DRMA) is 5.53% of its float. Check the ownership tab for more information on the DRMA short interest.
DRMA Technical Analysis
DRMA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DRMA. The financial health of DRMA is average, but there are quite some concerns on its profitability.
DRMA Financial Highlights
Over the last trailing twelve months DRMA reported a non-GAAP Earnings per Share(EPS) of -8.73. The EPS increased by 68.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -347.7% | ||
| ROE | -787.11% | ||
| Debt/Equity | 0 |
DRMA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to DRMA. The Buy consensus is the average rating of analysts ratings from 7 analysts.